Broadcom named strategic vendor for Walmart virtualization solutions
Investing.com - Deutsche Bank lowered its price target on Alcon Inc. (SWX:ALC) (NYSE:ALC) to CHF69.00 from CHF80.00 on Tuesday, while maintaining a Hold rating on the eye care company’s stock. The stock, currently trading at $80.76, is near its 52-week low of $78.11, though InvestingPro analysis suggests slight undervaluation based on Fair Value metrics.
Deutsche Bank cited concerns about when softer end markets will recover, noting that Alcon’s visibility into market conditions appears limited at present. This sentiment is reflected in recent analyst actions, with InvestingPro data showing five analysts revising their earnings estimates downward for the upcoming period.
The bank expressed skepticism about Alcon meeting its reduced full-year guidance, stating that achieving these targets would require "a meaningful acceleration in the second half, with phasing likely weighted toward Q4."
Deutsche Bank also suggested that 2026 consensus estimates for Alcon might be overly optimistic, and warned that the company’s medium-term guidance could require reduction if next year fails to show meaningful improvements in growth and margins.
Following this analysis, Deutsche Bank reduced its adjusted EPS estimates for Alcon for the current year and subsequent years, resulting in the lower price target.
In other recent news, Alcon Inc. has faced several adjustments in analyst ratings and price targets following its latest financial updates. Bernstein SocGen Group lowered its price target for Alcon to $104.65, maintaining an Outperform rating, after a disappointing second quarter that included an earnings miss and a guidance downgrade. JPMorgan also downgraded Alcon from Overweight to Neutral, citing a soft quarter and reduced guidance, and adjusted its price target to CHF62.80. BofA Securities reduced its price target to $100, maintaining a Buy rating, after Alcon issued a profit warning due to lower surgical procedure volumes and increased competition.
Additionally, Wells Fargo lowered its price target to $88, maintaining an Equal Weight rating, after Alcon revised its fiscal year 2025 revenue guidance downward. The new guidance suggests 4-5% growth, excluding foreign exchange effects, compared to the previous 6-7% growth outlook. Mizuho also reduced its price target to $110, maintaining an Outperform rating, attributing the adjustment to slower growth in the eye-care market, particularly affecting Alcon’s Surgical segment. These developments reflect broader concerns among analysts regarding Alcon’s future growth prospects and market conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.